Ask AI

Beyond Resistance: Integrating Next-Generation SERDs Into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer

Gain expert insights into the latest clinical data and recommendations on next-generation SERDs to optimize care and improve outcomes in patients with ER-positive/HER2-negative advanced breast cancer through a ClinicalThought commentary and certified on-demand webcast with accompanying downloadable slides.

Share

Program Content

Activities

SERDs for ERpos HER2neg ABC
Beyond Resistance: Integrating Next-Generation SERDs Into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 28, 2026

Activities

SERDs for ERpos HER2neg ABC
Beyond Resistance: Integrating Next-Generation SERDs Into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2026

Expires: December 16, 2026

Activities

FAQ on Endocrine-Resistant ER Positive HER2 Negative MBC
Practical Questions and Answers on the Current Management of Endocrine-Resistant ER+/HER2- Metastatic Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 14, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

Supported by educational grants from Lilly, Rigel Pharmaceuticals, Inc., and Stemline Therapeutics, Inc. 

Lilly

Rigel Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.